Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple drug help people with fluid on the brain walk better?

NCT ID NCT04975269

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug acetazolamide can improve walking in people with normal pressure hydrocephalus (NPH), a condition where excess fluid in the brain causes trouble walking, thinking, and bladder control. Fifty adults with NPH were randomly assigned to receive either acetazolamide or a placebo until they had shunt surgery. The main goal was to see if the drug improved gait function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Feb 2022

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 82 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of idiopathic normal pressure hydrocephalus according to international guidelines 2. Age ≥ 50 years and ≤ 82 years 3. Cognitive function with Mini-Mental State Examination \> 20 points or cognitive domain of iNPH scale ≥ 30 points. 4. MRI image characteristic of normal pressure hydrocephalus, defined as callosal angle \< 90 degrees and dilated lateral ventricles or pattern of disproportionately enlarged subarachnoid space hydrocephalus (DESH). 5. Signed informed consent form Exclusion Criteria: 1. Exclusion criteria for MRI examination 2. Participation in another medical trial 3. Other disease likely to impact the symptoms of the patient 4. Wheelchair user or unable to walk without support 5. Reduced kidney function with GFR \< 50 6. Reduced liver function (increased INR or alanine transaminase concentrations in plasma elevated more than 1.5 times reference values) 7. Known heart failure 8. Low concentrations of electrolytes in blood plasma that, according to the investigator, prevents participation in the study 9. Angle-closure glaucoma 10. Allergy to acetazolamide, sulfonamides, or sulfonamide derivatives 11. Treatment with phenytoin, valproate, carbamazepine, lithium, oral anticoagulants, thiazide-diuretics, or acetylsalicylic acid \> 100 mg/day 12. Inability to swallow capsules of the same size as the investigational medicinal products (will be tested using empty capsules when the patient is asked to participate in the study) 13. Average walking time for the three walking tests \< 10.5 seconds for men and \< 11.5 seconds for women. 14. Average walking time for the three walking tests \> 50 seconds 15. Inability to comply with the study treatment independently, and a concurrent lack of individuals to help the patient comply with the treatment during the study period 16. Fertile woman without highly effective contraception. A Fertile woman will be tested with pregnancy test before inclusion is possible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic normal pressure hydrocephalus (INPH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Clinical Neurophysiology, Neurosurgery and Neurology, Uppsala University Hospital

    Uppsala, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.